New study targets lung cancer in black patients: can immunotherapy improve outcomes?

NCT ID NCT06745882

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This phase 2 trial is testing the immunotherapy drug pembrolizumab, given alone or with chemotherapy, in 318 Black patients with advanced non-small cell lung cancer. The goal is to see how well these treatments work in real-world settings and to find biological markers that predict response. Participants must be newly diagnosed and have no certain gene mutations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (immunotherapy) combined with chemotherapy drugs (cisplatin, carboplatin, pemetrexed, abraxane, or paclitaxel)
What this could lead to: If successful, this trial could show that pembrolizumab-based treatment works well for Black patients with advanced lung cancer and help identify who benefits most.
What could go wrong: This is a phase 2 study, not designed for regulatory approval, so results may not change standard care. The small, single-race cohort may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Baptist Clinical Research Institute
RECRUITING

Memphis, Tennessee, 38120, United States
FirstHealth of the Carolinas, Inc.
RECRUITING

Pinehurst, North Carolina, 28374, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Montefiore Medical Cancer Center
RECRUITING

The Bronx, New York, 10461, United States
Nashville General Hospital
RECRUITING

Nashville, Tennessee, 37208, United States
TidalHealth Peninsula Regional
RECRUITING

Salisbury, Maryland, 20801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.